Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22657409 | 0.81 | HDAC1 (0.47) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL34469713 | 0.79 | AAK1 (0.45) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL5517439 | 0.79 | AAK1 (0.45) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL2147161 | 0.78 | HTT (0.42) | NPC1LMNASMN1; SMN2KMT2ACTSL | |
| SCHEMBL1345974 | 0.78 | HDAC4 (0.43) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL29581091 | 0.76 | DGAT1 (0.43) | DGAT1NPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL351360 | 0.76 | DGAT1 (0.43) | DGAT1NPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL29993320 | 0.75 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL4964802 | 0.74 | DGAT1 (0.42) | DGAT1NPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL28369708 | 0.73 | HDAC4 (0.43) | DGAT1NPC1ALDH1A1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| EP-3240784-A2 | INHIBITORS OF AKT KINASE | BerGenBio ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016102672-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | HDAC3 1259/4885HDAC1 1965/4885HDAC2 938/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | HDAC3 1658/4885HDAC1 2286/4885HDAC2 1111/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | HDAC3 1259/4885HDAC1 1965/4885HDAC2 938/4885 |
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | HDAC3 1843/4885HDAC1 1162/4885HDAC2 1590/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | HDAC3 1946/4885HDAC1 1196/4885HDAC2 1628/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | HDAC3 1946/4885HDAC1 1196/4885HDAC2 1628/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | HDAC3 1843/4885HDAC1 1162/4885HDAC2 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.